Patent Proofreading & Objection Support

PNPC coordinates the commercial, technical-documentation, and calendar-discipline side of the engagement: proofreading specifications and claims before filing or before a response is due, categorising FER objections, facilitating the claim-amendment strategy conversation with the inventor, compiling evidence and technical framing for Section 3 objections, and tracking every statutory deadline. The actual legal representation before the Controller — drafting and signing the formal FER response, appearing at a hearing, filing a Form 4 extension or a Form 13 amendment — is done by PNPC's empanelled registered patent agent or patent attorney, since only such persons are entitled to represent an applicant before the Patent Office under Section 129 of the Patents Act 1970.

An FER is the Examiner's first substantive report on a patent application after the Request for Examination (Form 18 or the expedited Form 18A) has been processed and examination has taken place. It lists every objection the Examiner has identified — typically covering novelty, inventive step, Section 3 patentability exclusions, claim clarity, unity of invention, and formal compliance. Receiving an FER with objections is the normal course of examination, not an indication the application has failed — the substantial majority of applications receive at least one FER with objections that must be addressed before grant.

Under Section 21 of the Patents Act as implemented by the Patents (Amendment) Rules 2024, the applicant has six months from the date the FER is issued to put the application in order for grant. This period can be extended by three months on a Form 4 request with the prescribed fee, filed before the original six-month period expires (or, following the 2024 amendment's added flexibility, the extension request can be made even shortly after the original period lapses). The outer limit is twelve months from the FER date — if the application is not placed in order for grant by then, it is deemed abandoned under Section 21(1).

If the application is not placed in order for grant within the twelve-month outer limit from the FER date, it is deemed to have been abandoned under Section 21(1) of the Patents Act. An abandoned application generally cannot be revived through a simple request — the applicant loses the benefit of the original filing/priority date for that invention, meaning a fresh application (if novelty has not since been destroyed by the applicant's own earlier-published application) starts with a later priority date and reduced patent term potential.

The patent agent reviews the cited references directly — not just the Examiner's summary of them — because cited prior art often discloses less than the objection implies, and a properly reasoned technical distinction can defeat the novelty or inventive-step objection without any claim amendment. Where the cited art genuinely does anticipate or render the claims obvious, the response typically involves narrowing the claims to add limiting features not present in the cited references, while preserving as much commercially meaningful scope as possible.

Section 3(k) excludes 'a mathematical or business method, a computer programme per se, or algorithms' from patentability. Most software-related FER objections cite this section. The response strategy is not to argue the invention 'isn't software' — it usually is — but to reframe the claims around a specific, demonstrable technical effect: improved processing efficiency, a novel technical interaction with hardware, solved network or security problems, and so on, following the approach reflected in the IPO's own Revised Guidelines for Examination of Computer Related Inventions. A claim drafted as an abstract method will struggle; a claim drafted around a concrete technical improvement has a real path to grant.

Section 3(d) excludes the mere discovery of a new form of a known substance — a new salt, polymorph, ester, or other derivative — unless it demonstrates significantly enhanced efficacy over the known substance. It is a factual, evidence-heavy objection: the response typically requires comparative test data or clinical/technical evidence showing the enhanced efficacy, not primarily legal argument. This section has been the subject of significant Supreme Court jurisprudence (notably in the Novartis Glivec case) establishing a strict standard for what counts as 'enhanced efficacy'.

A hearing notice under Rule 62 is issued when the Controller believes written responses have not fully resolved the FER objections, or when the applicant specifically requests one. It is procedural, not adversarial in the litigation sense — there is no opposing party at an FER-stage hearing; it is the applicant's patent agent presenting arguments (typically via video conference, or in person at the relevant IPO branch — Delhi, Mumbai, Chennai, or Kolkata) directly to the decision-maker, with the opportunity to propose further claim amendments in real time.

A pre-grant opposition under Section 25(1) is filed by a third party — a competitor, an interested party, or anyone with a stake in preventing the patent from being granted — while the application is still pending, on grounds such as lack of novelty, obviousness, prior claiming, or non-patentable subject matter. Unlike an FER, which comes from the Examiner as part of ordinary prosecution, a pre-grant opposition is adversarial: it involves a third party actively contesting the grant, and the applicant must file a reply statement with supporting evidence within the prescribed period.

Claims can be amended in response to an FER, but only within limits — amendments cannot introduce new matter beyond what was disclosed in the specification as originally filed (Section 59 of the Patents Act). This is why the original specification's breadth of disclosure matters enormously: an application that only described one narrow embodiment cannot later be amended to claim broader variations that were never described, even if those variations would have been patentable if disclosed at filing.

Section 8 requires an applicant to disclose details of corresponding patent applications filed in other countries for the same or substantially the same invention, and to keep the Controller updated on the status of those foreign applications until the Indian application is disposed of. Failure to make this disclosure, or failure to update it, is itself a ground the Examiner (or a later opponent) can raise, and in serious cases can be a ground for revocation post-grant under Section 64(1)(m). PNPC checks this systematically as part of objection support since it is frequently overlooked in applications with parallel foreign filings.

Yes. Expedited examination under Form 18A is available to a prescribed set of eligible applicants — including DPIIT-recognised startups, small entities, applicants where India was the International Searching Authority or International Preliminary Examining Authority in a corresponding PCT application, female applicants meeting the prescribed criteria, government undertakings, and certain other categories the Rules specify from time to time. The FER response deadlines and objection categories themselves are the same; what changes is the speed at which the FER is issued and subsequent actions are processed, which can matter significantly for a funding round or product launch timeline.

Yes, and this is one of the most cost-effective proofreading engagements PNPC offers. A specification drafted without close attention to claim construction, antecedent basis, and disclosure breadth often generates avoidable FER objections that a proper pre-filing or early post-filing review would have prevented or mitigated. While claims as filed generally cannot be broadened beyond the original disclosure, an early review can flag where the disclosure itself is thin, allowing supplementary or divisional strategies to be planned before it is too late.

PNPC charges a fixed, scoped professional fee for the coordination and proofreading work, agreed and confirmed in writing before the engagement begins. This is separate from the patent agent's professional fee for drafting and filing the actual response, and separate from any government fees (such as the Form 4 extension fee or hearing-related charges) payable to the Patent Office. Fees vary with the complexity of the objections, the technology area, and whether a hearing or opposition response is involved — a straightforward clarity objection costs materially less to resolve than a Section 3(d) objection requiring new comparative data.

No — only a registered patent agent or patent attorney (or the applicant in person, in narrow circumstances involving individual applicants) is legally entitled to represent an applicant before the Controller and file prosecution documents under Section 129 of the Patents Act 1970. A company applicant must be represented through an authorised patent agent. PNPC coordinates the process and proofreads content, but the response is drafted, signed, and filed by our empanelled registered patent agent.

No — DPIIT recognition and Udyam/MSME classification are independent of patent prosecution status; a pending FER, or even an eventually abandoned application, does not itself affect DPIIT or Udyam eligibility. However, unresolved patent objections can affect investor due diligence, licensing negotiations, or grant eligibility for schemes that specifically require a granted (not merely filed) patent, so the practical business impact can still be significant even though the statutory registrations themselves are unaffected.

The FER response must be filed by or on behalf of the applicant(s) of record — if multiple co-applicants are named, all generally need to act jointly through the same patent agent unless the application or an assignment agreement specifies otherwise. A dispute between co-inventors or co-applicants about strategy (e.g., how much to narrow claims, whether to pursue a hearing) needs to be resolved contractually between the parties; PNPC can facilitate this conversation, but cannot resolve an ownership dispute on the parties' behalf — that may require separate legal advice on the underlying assignment or collaboration agreement.

Investors and acquirers conducting IP due diligence routinely ask for the prosecution history of every pending patent application — including any FERs received, responses filed, deadlines pending, and any pre-grant oppositions. An unresolved or poorly documented FER response history is a common diligence flag, not because objections are unusual, but because it signals whether the company's IP management is disciplined. PNPC prepares a clean prosecution-status summary as part of diligence readiness work, alongside our broader fundraising and due-diligence support services.

The underlying examination framework and FER timelines under Section 21 apply the same way once a PCT application enters the Indian national phase and a Request for Examination is filed. What can differ is the prior art landscape the Examiner cites — international search and examination reports generated during the PCT process (ISR/IPER) are often referenced by the Indian Examiner, and applicants who were the International Searching Authority applicant for the same PCT family may also be eligible for expedited examination under the relevant Form 18A criteria.

A unity of invention objection under Section 10(5) arises when the Examiner considers the application to claim more than one distinct inventive concept. The applicant can either elect one invention to prosecute in the current application and abandon the others, or file one or more divisional applications under Section 16 to pursue the other inventive concepts separately, each retaining the parent application's original filing/priority date. Filing a divisional has its own procedural deadline tied to the parent application's pendency, so this decision needs to be made promptly once a unity objection is raised.

Yes — an applicant can voluntarily abandon or withdraw an application at any stage instead of continuing to respond to objections, though this forfeits the priority date and any protection for the invention as claimed. This is occasionally the right commercial decision where the cost of continued prosecution (narrowing claims to something commercially unhelpful, or funding extensive Section 3(d) evidence generation) outweighs the value of the eventual protection. PNPC helps evaluate this as a genuine option, not a failure — sometimes the correct answer to a weak FER position is a fresh, better-drafted application rather than fighting for a narrow grant on the existing one.

Yes, the empanelled patent agent coordinates translation and technical review of foreign-language prior art cited in an FER — this is common where the Examiner cites Japanese, Chinese, German, or Korean patent literature, which forms a substantial share of global patent prior art in many technology areas. A response cannot properly distinguish a reference that has not been accurately understood, so translation quality matters as much as the legal argument built on it.

Not immediately. Once the Controller is satisfied that the application is in order for grant, the patent is sealed and the grant is published in the Patent Office Journal. There can still be a gap of some weeks between the response being accepted and formal grant, and a pre-grant opposition remains possible for as long as the application is pending (i.e., until grant). After grant, the patent still faces a limited post-grant opposition window and ongoing renewal (annuity) fee obligations to keep it in force for its 20-year term from the filing date.

The FER response procedure and statutory deadlines under Section 21 are the same regardless of applicant category. What differs by applicant category (natural person, startup, small entity, or large entity, as defined under the Patent Rules) are certain government fees — including Request for Examination fees, and fees for some other prescribed actions — which are typically lower for individuals, startups, and small entities than for other applicants. This fee differential does not extend to relaxing the response deadlines themselves.

PNPC's Dubai office coordinates directly with the India team so a UAE-based applicant does not need to manage the India-side patent agent relationship, FER deadlines, and hearing logistics without local support. This is particularly relevant where the underlying R&D happened in India (raising employment/assignment ownership questions) or where the UAE entity is the applicant of record for an India-filed application as part of a broader India-UAE IP strategy.

The registered patent agent or patent attorney is the only person legally entitled to draft, sign, and file documents before the Controller — that professional role cannot be outsourced or replaced. PNPC's role is coordination, proofreading, business-context integration (funding timeline, DPIIT/MSME status, cap table and ownership documentation, cross-border considerations), and deadline discipline across the client's full compliance calendar — not a substitute for, but a complement to, the patent agent's technical-legal work. For clients who already have a strong direct relationship with a patent attorney, PNPC's role can be narrower — proofreading and deadline tracking only — while the attorney handles strategy and filing independently.

A patent agent working in isolation sees the FER as a technical-legal document to answer. PNPC sits alongside that relationship and connects it to the rest of the business: is this the moment to also check DPIIT/Udyam status for fee benefits, does an approaching funding round change how much claim scope we should concede, is the Section 8 foreign-filing disclosure actually current, does the response affect a licensing term sheet already under discussion, and is every deadline visible on the same compliance calendar as GST, MCA, and tax deadlines rather than tracked separately and at risk of falling through a gap. We have been doing this integration for clients across India and the UAE since 1986.

No. FER objections are a routine part of examination and say nothing directly about commercial value — they say the Examiner has found technical or legal issues with the claims as currently drafted, which is normal even for genuinely valuable inventions. What determines commercial value is the scope and strength of the claims that eventually get granted after the objections are resolved, which is precisely why the response strategy (rather than simply 'making the objection go away') matters so much.

The most recurring avoidable errors PNPC sees: claims using terms not defined or supported anywhere in the specification (triggering Section 10(4)/10(5) clarity objections); claims drafted more broadly than any disclosed embodiment (inviting both clarity and inventive-step objections); software claims phrased as abstract methods without describing any concrete technical effect (inviting Section 3(k) objections that are hard to overcome without new matter); inconsistent terminology between the claims and the description (e.g., calling the same component two different names); and missing or incomplete disclosure of known prior art the inventor was actually aware of at filing.

No — even a carefully drafted application can receive FER objections, particularly novelty or inventive-step objections based on prior art the Examiner locates that was not identified in the original search (Examiners have access to the same and sometimes additional databases). Proofreading materially reduces the number and severity of objections, particularly avoidable clarity, Section 3, and formal defects, but it cannot eliminate the possibility of a genuine prior-art-based objection that a proper original search did not surface.

Design registration objections under the Designs Act 2000 follow an entirely different statutory framework, examination process, and timeline from patent FERs — they are a much narrower, faster registration process focused on visual/ornamental features rather than technical invention. PNPC's design registration service handles design objections separately; this patent objection support service is specific to the Patents Act 1970 examination process.

A pre-filing or pre-response proofreading-only engagement — reviewing an existing draft specification and claims without an active FER deadline — is priced as a scoped, fixed-fee review, typically lower cost and shorter turnaround than active FER objection support, since there is no statutory clock and no need for prior-art re-litigation or claim-amendment negotiation under time pressure. Full FER objection support is priced based on the number and complexity of objections, technology area, and whether a hearing or opposition is involved.

The full prosecution history — the original application as filed, the FER, the response filed (including all amendments and arguments), any hearing notice and outcome, and the eventual grant certificate — should be retained as a complete file, since investors, acquirers, licensees, and (in a dispute) courts or the Controller may all need to review the complete prosecution history to understand what was claimed, argued, and conceded at each stage.

Filing the FER response itself does not attract a separate government fee in the ordinary course, but related actions can: a Form 4 extension of time request carries a prescribed fee, a Form 13 request for amendment of the application (in some circumstances) carries a fee, and a divisional application filed in response to a unity objection carries its own filing fee structure similar to an original application. PNPC confirms the applicable fee schedule for the specific actions needed in each case, since fee structures are periodically revised by the Patent Rules.

PNPC maintains a consolidated deadline calendar across all of a client's pending IP matters — patents, trademarks, designs — rather than tracking each application in isolation, so overlapping FER, hearing, and opposition deadlines across a growing patent portfolio are visible together and prioritised based on commercial urgency (e.g., an application tied to an active licensing negotiation gets priority attention over one with no immediate commercial trigger).